HIK Hikma Pharmaceuticals Plc

RNS Number:8907X
Hikma Pharmaceuticals Plc
06 June 2007


         Hikma Pharmaceuticals PLC - Results of Annual General Meeting


LONDON, 6 June 2007 - Hikma Pharmaceuticals PLC ("the Company") advises that at
its Annual General Meeting of shareholders, held at the London Underwriting
Centre, that began at 11.00am today, 6 June 2007, resolutions 1 to 8 and
resolution 10 contained in the Notice of Annual General Meeting were passed as
ordinary resolutions on a show of hands. Resolution 9 was passed as a special
resolution on a show of hands and resolution 11 was passed as an ordinary
resolution by way of a poll. The results of the poll are set out below:

Resolution 11                                         For             Against

Waiver of Rule 9 of the City Code on               39,201,592        2,150,591
Takeovers and Mergers

Copies of the resolutions dealing with special business passed at the Annual
General Meeting have been submitted to the UK Listing Authority for publication
through the Listing Authority's Document and Viewing Facility.

The total number of proxies received for each resolution is set out below.

      Resolutions                       For               Against         Vote
                                                                      withheld

  1   Receipt of accounts, together      45,853,772             0       31,478
      with reports of the Directors and
      auditors

  2   Declaration of final dividend      45,885,250             0            0

  3   Reappointment of Dr Ronald Goode   43,532,532     2,076,718      276,000
      as a Director of the Company

  4   Reappointment of Deloitte &        45,685,600        96,000      103,650
      Touche as auditors of the Company

  5   Authorise the Directors to set     45,885,200             0           50
      the remuneration of the auditors

  6   Approval of the Board report on    43,435,722     2,172,718      276,810
      remuneration

  7   Approval of electronic             45,885,250             0            0
      communications

  8   Authorise the Directors to allot   45,883,490         1,000          760
      relevant securities up to an
      aggregate nominal amount of
      #5,637,913

  9   Empower the Directors to allot     45,884,250         1,000            0
      equity securities for cash on a
      non pre-emptive basis up to an
      aggregate nominal amount of
      #845,687

 10   Authorise an increase in the       35,384,437    10,224,003      276,810
      maximum aggregate annual fees
      payable to the directors to
      #750,000

 11   Waiver of Rule 9 of the City Code  38,476,026     2,150,591    1,922,857
      on Takeovers and Mergers


The number of 10p ordinary shares in issue on 6 June 2007 was 169,137,407.

Waiver of Rule 9 of the City Code on Takeovers and Mergers

In relation to Resolution 11, at today's date, the total number of ordinary
shares held by the Concert Party, is 60,550,416, representing a combined
shareholding of 35.800% of the issued share capital of the Company. Assuming
that LTIP Awards are made in respect of the full number of shares referred to in
the circular to shareholders dated 25 April 2007, that all such grants vest in
full, that all Options currently held by members of the Concert Party were to be
fully exercised and the resulting Ordinary Shares retained by the Concert Party
members, the Concert Party would hold, in aggregate, interests over 62,659,557
Ordinary Shares, representing 36,590 per cent. of the issued share capital of
the Company (as enlarged by the Option Exercises by members of the Concert Party
and the issue of Ordinary Shares to members of the Concert Party pursuant to the
LTIP Awards, but assuming no other issue of shares) versus 36.428 per cent. of
the issued share capital of the Company on a similar basis, prior to the grant
of such LTIP Awards.


Declaration of final dividend

The final dividend of 4.0 cents per share will be paid on 18 June 2007 to
shareholders on the register on 18 May 2007. Shareholders who are not resident
in Jordan have been given the option of receiving their dividend in Pounds
Sterling. The exchange rate in respect of this dividend is 1.9330 US dollars to
one Pound Sterling, equal to 2.007 pence per share. Shareholders resident in
Jordan have been given the opportunity to receive the dividend in Jordanian
Dinar, at a rate of 0.708 Jordanian Dinar per US dollar.


                                    - ENDS -


Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles                                     +44 20 7399 2670
Company Secretary

Susan Ringdal                                     +44 20 7399 2670
Investor Relations Director


Brunswick Group

Jon Coles / Justine McIlroy / Alex Tweed          +44 20 7404 5959


About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the Middle East and
North Africa ("MENA") region, the United States and Europe. In 2006, the Group
had revenue of $317 million and profit attributable to shareholders of $55
million. At 31 December 2006, the Group had over 2,443 employees. For news and
other information, please visit www.hikma.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
AGMSSLFDMSWSEEM

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024